Literature DB >> 11956265

Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.

U N M Rao1, J Ibrahim, L E Flaherty, J Richards, J M Kirkwood.   

Abstract

PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFN alpha)-2b. PATIENTS AND METHODS: E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months' follow-up and studied using Cox regression analysis.
RESULTS: Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P =.0008) and OS (P =.05). ECS correlated with RFS (hazard ratio = 1.44, P =.032) but not OS (P =.11).
CONCLUSION: The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P =.0008) and OS (P =.053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956265     DOI: 10.1200/JCO.2002.08.024

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management.

Authors:  Michelle Lo; Alyss Robinson; Ryckie Wade; Howard Peach; Donald Dewar; Martin Heaton; Marc Moncrieff
Journal:  Ann Surg Oncol       Date:  2020-09-17       Impact factor: 5.344

2.  Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials.

Authors:  Uma N M Rao; Sandra J Lee; Weixiu Luo; Martin C Mihm; John M Kirkwood
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

3.  Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy.

Authors:  Edmund K Bartlett; Meera Gupta; Jashodeep Datta; Phyllis A Gimotty; DuPont Guerry; Xiaowei Xu; David E Elder; Brian J Czerniecki; Douglas L Fraker; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2013-11-21       Impact factor: 5.344

4.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

5.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

Review 6.  Emerging Biomarkers in Cutaneous Melanoma.

Authors:  Anna Eisenstein; Estela Chen Gonzalez; Rekha Raghunathan; Xixi Xu; Muzhou Wu; Emily O McLean; Jean McGee; Byungwoo Ryu; Rhoda M Alani
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

7.  Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson
Journal:  CA Cancer J Clin       Date:  2017-10-13       Impact factor: 508.702

8.  Cutaneous head and neck squamous cell carcinoma with regional metastases: the prognostic importance of soft tissue metastases and extranodal spread.

Authors:  Wendy Kelder; Ardalan Ebrahimi; Veronique-Isabelle Forest; Kan Gao; Rajmohan Murali; Jonathan R Clark
Journal:  Ann Surg Oncol       Date:  2011-08-09       Impact factor: 5.344

9.  Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center.

Authors:  Kenjiro Namikawa; Phyu P Aung; Jeffrey E Gershenwald; Denái R Milton; Victor G Prieto
Journal:  Cancer Med       Date:  2018-02-21       Impact factor: 4.452

10.  External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma.

Authors:  N A Ipenburg; O E Nieweg; T Ahmed; R van Doorn; R A Scolyer; G V Long; J F Thompson; S Lo
Journal:  Br J Surg       Date:  2019-07-16       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.